文献速递疼痛医学

鞘内药物输注系统的成本效果证据综述

Intrathecal drug delivery systems: an overview of cost-effectiveness evidence.
PubMed 文献 · Reg Anesth Pain Med · 2026-09-08

本文概述了卫生经济评价原则及鞘内药物输注(ITDD)系统在癌痛、慢性非癌痛和痉挛中的成本效果证据。多数分析提示ITDD较常规管理具成本效果,尤其癌痛和痉挛,但方法异质性和效果数据来源有限削弱了结论稳健性,慢性非癌痛证据尤其稀疏。

要点

  • 多数分析提示ITDD对癌痛和痉挛具成本效果
  • 慢性非癌痛的成本效果证据稀疏且不一致
  • 方法异质性和小样本效果数据限制证据稳健性

核心结论

  • 多数分析提示ITDD相比常规管理策略具成本效果,尤其癌痛和痉挛。
  • 慢性非癌痛证据尤其稀疏且不一致,需更严谨设计的研究。

研究设计与样本

  • 综述纳入已发表的全经济和部分经济评价研究,涉及不同视角和医疗环境。

主要发现

  • 多数分析提示ITDD对癌痛和痉挛具成本效果。
  • 慢性非癌痛的成本效果证据稀疏且不一致。
  • 证据稳健性受方法异质性和依赖小样本或非对照研究的效果数据限制。

临床怎么用

  • 决策者可参考ITDD对癌痛和痉挛具成本效果的证据,但需注意方法学局限。
  • 慢性非癌痛应用ITDD时应谨慎,因成本效果证据不一致。

局限性

  • 方法学异质性限制 findings 稳健性。
  • 效果数据常来自小样本或非对照研究。
  • 慢性非癌痛证据稀疏且不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Economic evaluations, which systematically compare the costs and health-related outcomes of health interventions, are essential for informing resource allocation decisions, particularly in the context of financial constraints and limited healthcare budgets. Intrathecal drug delivery (ITDD) systems are widely used for the management of cancer pain, chronic non-cancer pain, and spasticity. However, ITDD involves substantial upfront costs, ongoing maintenance expenses, and potential complications. This article provides an overview of health-related economic evaluation principles and of the evidence on the cost-effectiveness of ITDD systems across cancer pain, chronic non-cancer pain, and spasticity. Published studies include both full and partial economic evaluations, conducted from varying perspectives and in diverse healthcare settings. Most analyses suggest that ITDD is cost-effective compared with conventional management strategies, particularly for cancer-related pain and spasticity. However, the robustness of these findings is limited by methodological heterogeneity and reliance on effectiveness data that are often derived from small or uncontrolled studies. Evidence for chronic non-cancer pain is especially sparse and inconsistent, highlighting the need for further research using rigorous designs and comprehensive cost data. Given the high costs and complexity of ITDD systems, strengthening the evidence base on their clinical and economic value is critical to support informed decision-making by health technology assessment bodies and payers. Future studies should prioritize comparative effectiveness research and long-term economic modeling to address current gaps and uncertainties.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Duarte RV, Andronis L, Eldabe S, et al. Intrathecal drug delivery systems: an overview of cost-effectiveness evidence. Reg Anesth Pain Med. 2026. PMID: 42710953. doi:10.1136/rapm-2025-107218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。